Vascular Biogenics Ltd reports results for the quarter ended in September - Earnings Summary

Notable Labs

14/11/2022 22:00

* Vascular Biogenics Ltd  VBLT.OQ  reported a quarterly
adjusted
loss of 12 cents​​ per share for the quarter ended in September.
The mean expectation of four analysts for the quarter was for a
loss of 11 cents per share.
    * Revenue rose 151.3% to $500.00 thousand from a year ago;
analysts expected $200.00 thousand. 
    * Vascular Biogenics Ltd's reported EPS for the quarter was
a loss
of 12 cents​.
    * The mean earnings estimate of analysts had risen by
about 4.3%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Vascular Biogenics Ltd shares had fallen by 22.0% this
quarter and lost 93.8% so far this year.
    * The company reported a quarterly loss of $9.2 million.
    * Wall Street's median 12-month price target for Vascular
Biogenics Ltd is $5.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
14 at 09:59 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.11          -0.12          Missed
 Jun. 30 2022      -0.10          -0.12          Missed
 Mar. 31 2022      -0.11          -0.13          Missed
 Dec. 31 2021      -0.09          -0.12          Missed